Histologic, immunophenotypic, and PCR findings in KSHV MCD
| Case no. . | HIV . | EBV . | Diagnosis and KSHV-associated lesions . | Plasmablasts . | KSHV LNA . | KSHV* vIL6 . | Plasmablasts Ig . | Fr3-JH . | Fr3-Jλ . |
|---|---|---|---|---|---|---|---|---|---|
| MCD | P | P | |||||||
| 1 | − | − | Microlymphoma (Sp) | + | + | + | IgMλ | M | M |
| Plasmablastic lymphoma (LN) | M | M | |||||||
| MCD | P | P | |||||||
| 2 | + | − | Microlymphoma (Sp) | + | + | + | IgMλ | P | P |
| MCD | P | P | |||||||
| 3 | − | − | Microlymphoma (LN) | + | + | + | IgMλ | P | P |
| MCD | P | P | |||||||
| 4 | + | − | Microlymphoma (Sp) | + | + | + | IgMλ | M | M |
| MCD | P | P | |||||||
| 5 | + | − | Microlymphoma (Sp) | + | + | + | IgMλ | P | P |
| Plasmblastic lymphoma (LN) | M | P | |||||||
| MCD | P | P | |||||||
| 6 | + | − | Microlymphoma (Sp) | + | + | ND | IgMλ | P | P |
| MCD | P | P | |||||||
| 7 | + | − | Microlymphoma (Sp) | + | + | ND | IgMλ | P | ND |
| MCD | ND | ND | |||||||
| 8 | + | − | Microlymphoma (Sp) | + | + | ND | IgMλ | ND | ND |
| MCD | P | ND | |||||||
| 9 | + | − | Microlymphoma (LN) | + | + | + | IgMλ | P | ND |
| 10 | + | − | MCD | + | + | + | IgMλ | P | ND |
| 11 | + | − | MCD | + | + | ND | IgMλ | P | P |
| 12 | + | − | MCD | + | + | + | IgMλ | P | P |
| 13 | + | − | MCD | + | + | ND | IgMλ | P | ND |
| Case no. . | HIV . | EBV . | Diagnosis and KSHV-associated lesions . | Plasmablasts . | KSHV LNA . | KSHV* vIL6 . | Plasmablasts Ig . | Fr3-JH . | Fr3-Jλ . |
|---|---|---|---|---|---|---|---|---|---|
| MCD | P | P | |||||||
| 1 | − | − | Microlymphoma (Sp) | + | + | + | IgMλ | M | M |
| Plasmablastic lymphoma (LN) | M | M | |||||||
| MCD | P | P | |||||||
| 2 | + | − | Microlymphoma (Sp) | + | + | + | IgMλ | P | P |
| MCD | P | P | |||||||
| 3 | − | − | Microlymphoma (LN) | + | + | + | IgMλ | P | P |
| MCD | P | P | |||||||
| 4 | + | − | Microlymphoma (Sp) | + | + | + | IgMλ | M | M |
| MCD | P | P | |||||||
| 5 | + | − | Microlymphoma (Sp) | + | + | + | IgMλ | P | P |
| Plasmblastic lymphoma (LN) | M | P | |||||||
| MCD | P | P | |||||||
| 6 | + | − | Microlymphoma (Sp) | + | + | ND | IgMλ | P | P |
| MCD | P | P | |||||||
| 7 | + | − | Microlymphoma (Sp) | + | + | ND | IgMλ | P | ND |
| MCD | ND | ND | |||||||
| 8 | + | − | Microlymphoma (Sp) | + | + | ND | IgMλ | ND | ND |
| MCD | P | ND | |||||||
| 9 | + | − | Microlymphoma (LN) | + | + | + | IgMλ | P | ND |
| 10 | + | − | MCD | + | + | + | IgMλ | P | ND |
| 11 | + | − | MCD | + | + | ND | IgMλ | P | P |
| 12 | + | − | MCD | + | + | + | IgMλ | P | P |
| 13 | + | − | MCD | + | + | ND | IgMλ | P | ND |
MCD indicates multicentric Castleman disease; LN, lymph node; Sp, spleen; P, polyclonal; M, monoclonal; ND, not done.
KSHV vIL-6 was expressed in 10% to 15% of KSHV-positive plasmablasts.